PA Bio

PABio is a South Korean biotechnology company specializing in the development of next-generation bispecific antibody therapeutics for oncology. The company utilizes its proprietary PIGS (Primate-derived Immune Gene System) platform to discover high-affinity antibodies that are cross-reactive between humans and non-human primates, facilitating more accurate preclinical safety and efficacy testing. PABio's lead candidate, PAB001, is a bispecific antibody targeting TIE2 and VEGF designed to inhibit tumor angiogenesis and normalize the tumor vasculature. The company is also advancing a pipeline of immuno-oncology agents, including PD-L1 and 4-1BB bispecifics, to enhance anti-tumor immune responses while minimizing systemic toxicity. By focusing on dual-targeting mechanisms, PABio aims to overcome resistance in the tumor microenvironment and provide more effective treatment options for patients with solid tumors.